Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light

Hei, Derek J.; Grass, Joshua A.; Lin, Lily; Corash, Laurence; Cimino, George D.

doi:10.1046/j.1537-2995.1999.39399219279.x

Cited by 64 publications

(50 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This could be due to leukocyte inactivation, resulting in less cytokine production during storage of PCT platelets or the reduced volume of plasma in the PCT units. 43 Other adverse events, including hemorrhagic adverse events and death, were not different between the 2 groups of patients.…”

Section: Discussionmentioning

confidence: 85%

Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial

McCullough

Vesole²,

Benjamin³

et al. 2004

Blood

365

579

View full text Add to dashboard Cite

We report a transfusion trial of platelets photochemically treated for pathogen inactivation using the synthetic psoralen amotosalen HCl. Patients with thrombocytopenia were randomly assigned to receive either photochemically treated (PCT) or conventional (control) platelets for up to 28 days. The primary end point was the proportion of patients with World Health Organization (WHO) grade 2 bleeding during the period of platelet support. A total of 645 patients (318 PCT and 327 control) were evaluated. The primary end point, the incidence of grade 2 bleeding (58.5% PCT versus 57.5% control), and the secondary end point, the incidence of grade 3 or 4 bleeding (4.1% PCT versus 6.1% control), were equivalent between the 2 groups (P ‫؍‬ .001 by noninferiority). The

show abstract

Section: Discussionmentioning

confidence: 85%

Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial

McCullough

Vesole²,

Benjamin³

et al. 2004

Blood

365

579

View full text Add to dashboard Cite

show abstract

“…Photochemical treatment completely inhibited cytokine synthesis during platelet storage. 34 Gamma irradiation only reduced the levels of cytokines by approximately 40% during platelet storage. This observation is consistent with the level of nucleic acid modification achieved by photochemical treatment in contrast to that resulting from gamma irradiation since cytokines generally have DNA sequences of approximately 10 000 bp.…”

Section: Leukocyte Inactivation As Measured By Inhibition Of Cytokinementioning

confidence: 97%

“…Starting in 1989, a series of research publications examined the utility of existing psoralens (8-MOP and AMT) and novel psoralens (amotosalen HCl) for the inactivation of infectious pathogens and leukocytes in platelet and plasma blood components. [27][28][29][30][31][32][33][34][35][36] Recently, a photochemical process using amotosalen HCl has received European approval for inactivation of infectious pathogens and leukocytes in platelet components. 37 This technology utilizes the novel psoralen compound amotosalen HCl, formerly known as S-59, and long wavelength ultraviolet light (UVA) to induce the formation of irreversible, covalent psoralen-nucleic acid adducts ( Figure 2).…”

Section: Risk Factors For Ta-gvhd and Current Technologymentioning

confidence: 99%

Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease

Corash

Lin

2003

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Transfusion-associated graft-versus-host disease (TA-GVHD) is a serious complication of blood component transfusion therapy. Currently, cellular blood components for patients recognized at risk for TA-GVHD are irradiated prior to transfusion in order to prevent this complication. Considerable progress has been made in elucidating the pathophysiology of this highly morbid complication, but questions as to which patients are at risk and what is the most robust technology to prevent TA-GVHD remain. As new technologies for inactivating or modulating leukocyte function are introduced, the question of how to evaluate these technologies becomes relevant. Over the past two decades, a number of research groups have explored technology to inactivate infectious pathogens and leukocytes contaminating cellular blood components. Few clinicians have an in-depth understanding of the methods or the criteria for selection of how to approach new technologies for leukocyte inactivation with potential to replace current methods. This mini review focuses on the salient aspects of current and evolving technology for prevention of TA-GVHD.

show abstract

“…UVC irradiation failed to effectively inactivate spores (having a low impact in blood products), West Nile virus and especially HIV (for which screening is performed) [35,36]. Disruption irradiation to prevent transfusion-associated graft versus host disease due to the capacity to inactivate donor leukocytes [13][14][15].…”

Section: Uvc Irradiation Of Pcs and Plasmamentioning

confidence: 99%

Pathogen Reduction Technologies: The Best Solution for Safer Blood?

Picker¹

2013

J Blood Disord Transfus

View full text Add to dashboard Cite

Although it is generally accepted that blood has never been safer than today, transfusion-associated side effects, particularly infective, still occur. Unlike screening strategies, pathogen reduction technologies offer a new approach to increase blood safety by actively/directly targeting possible, also emerging pathogens or donor leukocytes. Advanced technologies for cellular blood products like the psoralen-based INTERCEPT BLOOD SYSTEM or the riboflavin-based Mirasol pathogen reduction technology system have extensively been examined and are on the way to enter the blood bank routine. However, as with any medical treatment, the transfusion of pathogen reduced blood products is not completely risk-free. Due to possible impairment of the treated blood cells the transfusion success is significantly lower as compared to untreated blood products. Long-term side effects concerning the photosensitizers and their photoproducts still remain a matter of debate. This paper outlines current pathogen reduction technologies but also focuses on ethical concerns associated with the employment of these techniques.

show abstract

Elimination of cytokine production in stored platelet concentrate aliquots by photochemical treatment with psoralen plus ultraviolet A light

Cited by 64 publications

References 32 publications

Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial

Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT Trial

Novel processes for inactivation of leukocytes to prevent transfusion-associated graft-versus-host disease

Pathogen Reduction Technologies: The Best Solution for Safer Blood?

Contact Info

Product

Resources

About